Page last updated: 2024-08-23

mifepristone and Uterine Neoplasms

mifepristone has been researched along with Uterine Neoplasms in 87 studies

Research

Studies (87)

Timeframe	Studies, this research(%)	All Research%
pre-1990	4 (4.60)	18.7374
1990's	23 (26.44)	18.2507
2000's	26 (29.89)	29.6817
2010's	29 (33.33)	24.3611
2020's	5 (5.75)	2.80

Authors

Authors	Studies
Chae, B; Kim, MR; Park, JY	1
Li, Q; Zhou, G	1
Shen, Q; Sheng, B; Sun, LZ; Zhao, M; Zhu, X; Zou, S	1
Bulun, SE; Coon V, JS; Dai, Y; Dotts, AJ; Kujawa, SA; Liu, S; Shilatifard, A; Xu, J; Yin, P; Zhao, H	1
Dong, X; Guo, R; Hai, N; Hou, Q	1
Peng, F; Shi, S; Ye, Q; Yu, C	1
Chow, TL; Murji, A; Sobel, ML; Whitaker, L	1
Hu, X; Luo, H; Shen, Q; Shu, L; Zhu, X	1
Belland, L; Leyland, N; Murji, A; Singh, SS; von Riedemann, S	1
Bouchard, P; Chabbert-Buffet, N; Daraï, E; Kolanska, K	1
Cui, S; Feng, Q; Liu, P; Wang, Z; Zhang, L	1
Cardini, F; Liu, JP; Xia, Y; Yang, H	1
Agarwal, N; Garg, P; Hari, S; Kriplani, A; Kulshrestha, V; Sareen, N; Thulkar, J	1
Chen, M; Hua, Y; Jiang, W; Shen, Q; Zhang, W; Zhu, X	1
Gilboa, Y; Goldchmit, C; Jakobson-Setton, A; Katz, D; Seidman, DS; Tadir, Y; Yerushalmi, GM	1
Byström, B; Engman, M; Gemzell-Danielsson, K; Hammarsjö, A; Lagerstedt Robinson, K; Lalitkumar, PG; Malmgren, H; Varghese, S	1
Bastianelli, C; Benagiano, G; Brosens, I; Farris, M	1
Abraham, T; Arian, SE; Bartels, CB; Cayton, KC; Chuong, FS; Holthouser, K; Segars, JH	1
Britten, J; Catherino, WH; Cox, J; Malik, M; Patel, A	1
Centini, G; Kashani, BN; Morelli, SS; Petraglia, F; Weiss, G	1
Bragg, B; Chawla, K; Hladky, K; Mark, K	1
Branchini, G; Brum, IS; Capp, E; Corleta, HVE; Pizzolato, LS; Sant'Anna, GDS	1
Akerman, G; Barranger, E; Desfeux, P; Malartic, C; Morel, O; Tulpin, L	1
Eisinger, S; Fiscella, K	1
Acosta, R; Carbonell Esteve, JL; Castañeda, MC; Heredia, B; Hernández, AV; Pérez, Y	1
Bouchard, P; Chabbert-Buffet, N; Ouzounian, S	1
Berry, E; Bulun, S; Chakravarti, D; Clardy, J; Hardt, J; Hoekstra, AV; Kim, JJ; Lu, Z; Marsh, E; Sefton, EC; Yin, P	1
Bagaria, M; Guleria, K; Mishra, K; Suneja, A; Vaid, NB	1
Erenbourg, A; Piccoli, M; Ronfani, L; Tamburlini, G	1
Engman, M; Gemzell-Danielsson, K; Granberg, S; Lalitkumar, PG; Meng, CX; Williams, AR	1
Fraser, IS	1
Bonfiglio, T; Eisinger, SH; Fiscella, J; Fiscella, K; Meldrum, S	1
Spitz, IM	2
Bulun, SE; Ishikawa, H; Lin, Z; Luo, X; Marsh, EE; Pavone, ME; Reierstad, S; Yin, P; Zhao, H	1
Appleman, LJ; Im, A	1
Bulun, SE; Chakravarti, D; Cheng, Y; Coon, JS; Innes, J; Ishikawa, H; Kim, JJ; Lin, Z; Marsh, EE; Pearson, K; Reierstad, S; Wu, J; Yin, P	1
Feng, C; Fiscella, K; Meldrum, S	1
Bulun, SE; Ishi, K; Ishikawa, H; Kakazu, R; Kurita, T; Serna, VA	1
Bulun, SE; Coon, JS; Ishikawa, H; Pearson, EK; Su, E	1
Csatlós, E; Joó, JG; Nagy, Z; Rigó, J; Szabó, I	1
Bonfiglio, T; Eisinger, SH; Fiscella, J; Fiscella, K; Winters, P	1
Bouchard, P	1
Acosta, R; Campos, R; Esteve, JL; Hernández, AV; Pérez, Y; Texidó, CS	1
Bulun, SE; Coon, JS; Dai, Y; Huang, L; Kim, JJ; Monsivais, D; Navarro, A; Owen, JK; Roqueiro, D; Xie, A; Yin, P	1
Angiolucci, M; Guerriero, S; Lello, S; Maricosu, G; Marotto, MF; Melis, GB; Orru', MM; Paoletti, AM; Pilloni, M; Piras, B	1
Orozco, LJ; Ramírez-Morera, A; Steed, A; Stone, P; Tristan, M	1
Schweppe, KW	1
Eisinger, SH; Fiscella, K; Guzick, DS; le Roux, HD; Meldrum, S	1
Jackson, R; Jacoby, AF; Pritts, EA; Steinauer, J	1
Dominguez, CE; Lowe, E; Murphy, AA; Parthasarathy, S; Ramachandran, S; Song, MQ	1
Chen, CL; Liao, QP; Lu, Y; Yu, L	1
Librach, CL; Xiao, R; Yie, SM	1
Eisinger, SH; Feng, C; Fiscella, K; Fisher, SG; Guzick, DS; Meldrum, S	1
Heikinheimo, O; Koivisto-Korander, R; Leminen, A	1
Lee, EW; Leung, PC; Mao, Q; Ross, DD; Unadkat, JD; Wang, H; Zhou, L	1
Kettel, LM; Morales, AJ; Murphy, AA; Yen, SS	2
Castellano, PZ; Murphy, AA	1
Bates, A; Evans, J; Pinto, A	1
Morales, AJ; Murphy, AA; Reinsch, RC; Yen, SS	1
Smith, SK	1
Courtieu, C; Déchaud, H; Marès, P; Marsollier, C; Tailland, ML	1
Kettel, LM; Morales, AJ; Murphy, AA; Roberts, VJ; Yen, SS	1
Kettel, LM	1
Kettel, LM; Morales, AJ; Murphy, AA	1
Bamberger, AM; Erdmann, I; Jenatschke, S; Schulte, HM	1
Li, K; Yang, Y; Zheng, S	1
London, SN; Mahajan, DK	1
Chi, CW; Ho, CK; Wang, SY; Yu, KJ	1
Sitruk-Ware, R	1
Yang, Y; Zhang, Z; Zheng, S	1
Sun, M; Zhou, L; Zhu, G	1
Gu, M; Huang, H; Zeng, C	1
Bright, N; Coleman, RE; Gillespie, AM; Hancock, BW; Radstone, CR; Tidy, JA	1
Boettger-Tong, H; Chiappetta, C; Huang, JC; Hyder, SM; Mäkelä, S; Nawaz, Z; Stancel, GM	1
Matsuda, M; Mitamura, T; Mori, T; Sakamoto, S; Zhou, YF	1
Weng, L	1
Jiang, M; Weng, L; Wu, S; Wu, Y	1
Sun, L; Wang, C; Zheng, Y	1
Jin, J; Wang, H	1
Jiang, J; Sun, HC; Wang, ZH; Wu, RF; Xiu, HM; Xu, Z	1
Azuma, C; Kimura, T; Miki, M; Ono, M; Saji, F; Takemura, M; Tanizawa, O; Tokugawa, Y	1
Bischof, P; Herrmann, WL; Schindler, AM; Sizonenko, PC; Wyss, R	1
Matsumoto, K; Shimizu, I; Tanizawa, O; Terakawa, N	1
Fujimoto, J; Fujita, H; Hosoda, S; Okada, H	1
Okada, H	1

Reviews

25 review(s) available for mifepristone and Uterine Neoplasms

Article	Year
The efficacy and safety of Xuefu Zhuyu Decoction combined with Mifepristone in the treatment of uterine leiomyoma: A systematic review and meta-analysis. Journal of ethnopharmacology, 2021, Dec-05, Volume: 281 Topics: Antineoplastic Agents; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Leiomyoma; Mifepristone; Uterine Neoplasms	2021
Selective progesterone receptor modulators (SPRMs) for uterine fibroids. The Cochrane database of systematic reviews, 2017, Apr-26, Volume: 4 Topics: Amenorrhea; Antineoplastic Agents, Hormonal; Estrenes; Female; Humans; Leiomyoma; Leuprolide; Menstruation; Mifepristone; Norpregnadienes; Oximes; Pelvic Pain; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Progesterone; Uterine Neoplasms	2017
The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids. American journal of obstetrics and gynecology, 2018, Volume: 218, Issue:6 Topics: Contraceptive Agents, Female; Disease Management; Estrenes; Female; Forecasting; Humans; Leiomyoma; Mifepristone; Norpregnadienes; Oximes; Population Growth; Receptors, Progesterone; Steroids; Uterine Neoplasms	2018
Selective progesterone receptor modulators: current applications and perspectives. Climacteric : the journal of the International Menopause Society, 2018, Volume: 21, Issue:4 Topics: Abortion, Induced; Endometriosis; Female; Humans; Leiomyoma; Mifepristone; Norpregnadienes; Pregnancy; Progesterone; Receptors, Progesterone; Uterine Hemorrhage; Uterine Neoplasms	2018
Herbal preparations for uterine fibroids. The Cochrane database of systematic reviews, 2013, Apr-30, Issue:4 Topics: Drugs, Chinese Herbal; Female; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Leiomyoma; Mifepristone; Phytotherapy; Plant Preparations; Randomized Controlled Trials as Topic; Uterine Neoplasms	2013
Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis. Fertility and sterility, 2013, Volume: 100, Issue:6 Topics: Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Humans; Incidence; Leiomyoma; Mifepristone; Premenopause; Risk Factors; Treatment Outcome; Uterine Neoplasms	2013
Selective progesterone receptor modulators: an update. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:10 Topics: Adenomyosis; Animals; Clinical Trials as Topic; Contraception, Postcoital; Contraceptive Agents, Female; Contraceptives, Postcoital; Endometriosis; Estrenes; Female; Hormone Antagonists; Humans; Leiomyoma; Levonorgestrel; Mifepristone; Norpregnadienes; Oximes; Receptors, Progesterone; Uterine Neoplasms	2014
An Evidence-based Approach to the Medical Management of Fibroids: A Systematic Review. Clinical obstetrics and gynecology, 2016, Volume: 59, Issue:1 Topics: Androgens; Aromatase Inhibitors; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Curcumin; Delayed-Action Preparations; Drugs, Chinese Herbal; Estradiol; Estrenes; Estrogen Receptor Antagonists; Evidence-Based Medicine; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Intrauterine Devices, Medicated; Leiomyoma; Levonorgestrel; Medroxyprogesterone Acetate; Mifepristone; Neoadjuvant Therapy; Norpregnadienes; Oximes; Plant Extracts; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tea; Uterine Myomectomy; Uterine Neoplasms; Vitamin D; Vitamins	2016
Role of Medical Management for Uterine Leiomyomas. Best practice & research. Clinical obstetrics & gynaecology, 2016, Volume: 34 Topics: Antifibrinolytic Agents; Aromatase Inhibitors; Cabergoline; Cholecalciferol; Contraceptive Agents, Female; Contraceptives, Oral, Hormonal; Contraceptives, Oral, Synthetic; Danazol; Dopamine Agonists; Ergolines; Estrenes; Estrogen Antagonists; Female; Gestrinone; Gonadotropin-Releasing Hormone; Humans; Intrauterine Devices, Medicated; Leiomyoma; Levonorgestrel; Mifepristone; Norpregnadienes; Oximes; Patient Care Planning; Selective Estrogen Receptor Modulators; Somatostatin; Tranexamic Acid; Uterine Neoplasms; Vitamins	2016
[Role of mifepristone for the treatment of uterine fibroid]. Gynecologie, obstetrique & fertilite, 2008, Volume: 36, Issue:6 Topics: Antineoplastic Agents, Hormonal; Dose-Response Relationship, Drug; Endometrial Hyperplasia; Female; Hot Flashes; Humans; Leiomyoma; Liver; Mifepristone; Treatment Outcome; Uterine Neoplasms	2008
Effects of antiprogestins on the uterus. Women's health (London, England), 2008, Volume: 4, Issue:3 Topics: Animals; Contraceptives, Oral, Synthetic; Female; Hormone Antagonists; Humans; Leiomyoma; Metrorrhagia; Mifepristone; Progestins; Receptors, Progesterone; Uterine Neoplasms; Uterus	2008
Clinical utility of progesterone receptor modulators and their effect on the endometrium. Current opinion in obstetrics & gynecology, 2009, Volume: 21, Issue:4 Topics: Drug Administration Schedule; Endometriosis; Endometrium; Estrenes; Female; Hormone Antagonists; Humans; Leiomyoma; Mifepristone; Norpregnadienes; Oximes; Randomized Controlled Trials as Topic; Receptors, Progesterone; Time Factors; Uterine Neoplasms	2009
Mifepristone: pharmacology and clinical impact in reproductive medicine, endocrinology and oncology. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:3 Topics: Abortifacient Agents, Steroidal; Drug Approval; Drug Delivery Systems; Drug Design; Endocrinology; Female; Humans; Medical Oncology; Mifepristone; Pregnancy; Pregnancy Complications, Neoplastic; Reproductive Medicine; Uterine Neoplasms	2010
[Uterine leiomyoma]. Orvosi hetilap, 2010, Oct-17, Volume: 151, Issue:42 Topics: Antineoplastic Agents; Diagnosis, Differential; Estrenes; Female; Hormone Antagonists; Humans; Hysterectomy; Incidence; Laparoscopy; Leiomyoma; Mifepristone; Oximes; Ultrasonic Therapy; Uterine Artery; Uterine Neoplasms	2010
Current and future medical treatments for menometrorrhagia during the premenopause. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2011, Volume: 27 Suppl 1 Topics: Adolescent; Adult; Contraceptives, Oral; Endometrial Neoplasms; Female; Gonadotropin-Releasing Hormone; Humans; Leiomyoma; Levonorgestrel; Menorrhagia; Metrorrhagia; Mifepristone; Norpregnadienes; Polyps; Premenopause; Progestins; Randomized Controlled Trials as Topic; Receptors, Progesterone; Uterine Neoplasms	2011
Mifepristone for uterine fibroids. The Cochrane database of systematic reviews, 2012, Aug-15, Issue:8 Topics: Female; Humans; Leiomyoma; Menorrhagia; Mifepristone; Premenopause; Randomized Controlled Trials as Topic; Receptors, Progesterone; Tumor Burden; Uterine Neoplasms	2012
Progestins and uterine leiomyoma. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 1999, Volume: 13 Suppl 4 Topics: Danazol; Estrogen Antagonists; Estrogens; Female; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Leiomyoma; Mifepristone; Progesterone; Progestins; Uterine Neoplasms	1999
Progesterone antagonists and progesterone receptor modulators. Expert opinion on investigational drugs, 2003, Volume: 12, Issue:10 Topics: Animals; Contraceptives, Postcoital; Drug Administration Schedule; Endometriosis; Endometrium; Female; Gene Transfer Techniques; Hormone Antagonists; Humans; Leiomyoma; Mifepristone; Progesterone; Receptors, Progesterone; Uterine Neoplasms	2003
Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstetrics and gynecology, 2004, Volume: 103, Issue:6 Topics: Adult; Clinical Trials as Topic; Endometrial Hyperplasia; Female; Hormone Antagonists; Humans; Leiomyoma; Middle Aged; Mifepristone; Uterine Neoplasms	2004
RU486: pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri. Current opinion in obstetrics & gynecology, 1994, Volume: 6, Issue:3 Topics: Endometriosis; Endometrium; Female; Humans; Leiomyoma; Mifepristone; Progesterone; Uterine Neoplasms	1994
Clinical applications of the antiprogestins. Clinical obstetrics and gynecology, 1995, Volume: 38, Issue:4 Topics: Abortifacient Agents, Steroidal; Breast Neoplasms; Clinical Trials as Topic; Contraceptives, Oral, Synthetic; Cushing Syndrome; Endometriosis; Endometrium; Female; Hormone Antagonists; Humans; Leiomyoma; Meningeal Neoplasms; Meningioma; Menstrual Cycle; Mifepristone; Pregnancy; Pregnancy, Ectopic; Premenstrual Syndrome; Progestins; Uterine Neoplasms	1995
Mifepristone: clinical application in general gynecology. Clinical obstetrics and gynecology, 1996, Volume: 39, Issue:2 Topics: Endometriosis; Endometrium; Female; Genital Diseases, Female; Hormone Antagonists; Humans; Leiomyoma; Menstrual Cycle; Mifepristone; Uterine Neoplasms	1996
Mifepristone (RU486): a review. Fertility and sterility, 1997, Volume: 68, Issue:6 Topics: Abortifacient Agents, Steroidal; Abortion, Induced; Animals; Breast Neoplasms; Contraceptives, Oral, Synthetic; Contraceptives, Postcoital, Synthetic; Endometriosis; Female; Humans; Leiomyoma; Mifepristone; Pregnancy; Uterine Neoplasms	1997
[Anti-progesterones]. Presse medicale (Paris, France : 1983), 1999, Dec-04, Volume: 28, Issue:38 Topics: Abortifacient Agents, Steroidal; Abortion, Therapeutic; Contraceptive Agents; Contraceptives, Oral, Synthetic; Endometriosis; Female; Humans; Leiomyosarcoma; Meningioma; Mifepristone; Pregnancy; Pregnancy Complications, Neoplastic; Progesterone; Progestins; Receptors, Progesterone; Uterine Neoplasms	1999
Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environmental health perspectives, 2000, Volume: 108 Suppl 5 Topics: Breast Neoplasms; Dose-Response Relationship, Drug; Endothelial Growth Factors; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Hormone Antagonists; Humans; Leiomyoma; Lymphokines; Mifepristone; Progestins; Receptors, Estrogen; RNA, Messenger; Signal Transduction; Transcription, Genetic; Uterine Neoplasms; Uterus; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2000

Trials

16 trial(s) available for mifepristone and Uterine Neoplasms

Article	Year
Low dose mifepristone in medical management of uterine leiomyoma - an experience from a tertiary care hospital from north India. The Indian journal of medical research, 2013, Volume: 137, Issue:6 Topics: Administration, Oral; Adult; Cost-Benefit Analysis; Drug Administration Schedule; Female; Follow-Up Studies; Hormone Antagonists; Humans; India; Leiomyoma; Menorrhagia; Middle Aged; Mifepristone; Prospective Studies; Tertiary Care Centers; Treatment Outcome; Uterine Neoplasms	2013
Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study. Fertility and sterility, 2014, Volume: 101, Issue:2 Topics: Administration, Intravaginal; Adult; Female; Hormone Antagonists; Humans; Israel; Leiomyoma; Middle Aged; Mifepristone; Prospective Studies; Surveys and Questionnaires; Treatment Outcome; Uterine Neoplasms	2014
GSTM1 gene expression correlates to leiomyoma volume regression in response to mifepristone treatment. PloS one, 2013, Volume: 8, Issue:12 Topics: Biomarkers; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glutathione Transferase; Hormone Antagonists; Humans; Leiomyoma; Mifepristone; Oligonucleotide Array Sequence Analysis; Premenopause; Receptors, Progesterone; Signal Transduction; Tumor Burden; Uterine Neoplasms; Uterus	2013
Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstetrics and gynecology, 2008, Volume: 112, Issue:5 Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Hormone Antagonists; Humans; Leiomyomatosis; Middle Aged; Mifepristone; Treatment Outcome; Ultrasonography; Uterine Neoplasms; Uterus	2008
Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. The Australian & New Zealand journal of obstetrics & gynaecology, 2009, Volume: 49, Issue:1 Topics: Adult; Double-Blind Method; Drug Administration Schedule; Endometrial Hyperplasia; Female; Follicular Phase; Hormone Antagonists; Humans; Leiomyomatosis; Menorrhagia; Middle Aged; Mifepristone; Placebos; Uterine Neoplasms	2009
Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human reproduction (Oxford, England), 2009, Volume: 24, Issue:8 Topics: Adult; Double-Blind Method; Female; Hemoglobins; Humans; Leiomyoma; Middle Aged; Mifepristone; Regional Blood Flow; Uterine Hemorrhage; Uterine Neoplasms; Uterus	2009
Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. European journal of obstetrics, gynecology, and reproductive biology, 2009, Volume: 146, Issue:2 Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Female; Health Status; Hormone Antagonists; Humans; Leiomyoma; Middle Aged; Mifepristone; Pain; Quality of Life; Uterine Hemorrhage; Uterine Neoplasms	2009
Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial. European journal of obstetrics, gynecology, and reproductive biology, 2012, Volume: 161, Issue:2 Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Double-Blind Method; Fatigue; Female; Follow-Up Studies; Hemoglobins; Hormone Antagonists; Hot Flashes; Humans; Leiomyoma; Menorrhagia; Middle Aged; Mifepristone; Nausea; Pelvic Pain; Uterine Neoplasms; Vomiting	2012
Low-dose mifepristone for uterine leiomyomata. Obstetrics and gynecology, 2003, Volume: 101, Issue:2 Topics: Adult; Biopsy, Needle; Blood Chemical Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Endosonography; Female; Follow-Up Studies; Hormone Antagonists; Humans; Immunohistochemistry; Leiomyoma; Middle Aged; Mifepristone; Multivariate Analysis; Reference Values; Statistics, Nonparametric; Treatment Outcome; Uterine Neoplasms	2003
Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstetrics and gynecology, 2006, Volume: 108, Issue:6 Topics: Adult; Female; Hormone Antagonists; Humans; Leiomyomatosis; Middle Aged; Mifepristone; Organ Size; Pain; Quality of Life; Treatment Outcome; Ultrasonography; Uterine Neoplasms; Uterus	2006
Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertility and sterility, 1995, Volume: 64, Issue:1 Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Female; Humans; Leiomyomatosis; Middle Aged; Mifepristone; Prospective Studies; Ultrasonography; Uterine Neoplasms	1995
Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Human reproduction (Oxford, England), 1994, Volume: 9 Suppl 1 Topics: Abdominal Pain; Adolescent; Adrenocorticotropic Hormone; Adult; Anovulation; Endometriosis; Estrogens; Female; Humans; Hydrocortisone; Leiomyoma; Luteinizing Hormone; Mifepristone; Pilot Projects; Progesterone; Ultrasonography; Uterine Neoplasms	1994
The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. American journal of obstetrics and gynecology, 1994, Volume: 170, Issue:6 Topics: Female; Humans; Leiomyoma; Leuprolide; Mifepristone; Prospective Studies; Regional Blood Flow; Uterine Neoplasms; Uterus	1994
[Treatment of uterine leiomyoma by two different doses of mifepristone]. Zhonghua fu chan ke za zhi, 1996, Volume: 31, Issue:10 Topics: Adult; Female; Hormone Antagonists; Humans; Leiomyoma; Middle Aged; Mifepristone; Prospective Studies; Uterine Neoplasms	1996
[Effects of mifepristone on gene expression of epidermal growth factor in human uterine leiomyoma]. Zhonghua fu chan ke za zhi, 1998, Volume: 33, Issue:1 Topics: Epidermal Growth Factor; Female; Gene Expression; Hormone Antagonists; Humans; Leiomyoma; Mifepristone; RNA, Messenger; Uterine Neoplasms	1998
[A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone]. Zhonghua fu chan ke za zhi, 1998, Volume: 33, Issue:8 Topics: Adult; Female; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Leiomyoma; Middle Aged; Mifepristone; Uterine Neoplasms	1998

Other Studies

46 other study(ies) available for mifepristone and Uterine Neoplasms

Article	Year
The Potential of Transforming Growth Factor-beta Inhibitor and Vascular Endothelial Growth Factor Inhibitor as Therapeutic Agents for Uterine Leiomyoma. International journal of medical sciences, 2022, Volume: 19, Issue:12 Topics: Female; Humans; Intercellular Signaling Peptides and Proteins; Leiomyoma; Mifepristone; Transforming Growth Factor beta; Transforming Growth Factor beta1; Transforming Growth Factors; Uterine Neoplasms; Vascular Endothelial Growth Factor A	2022
Long-term use of ultra-low-dose mifepristone for uterine leiomyoma control and safety discussion: A case report. Medicine, 2022, Dec-30, Volume: 101, Issue:52 Topics: Female; Hormone Antagonists; Humans; Leiomyoma; Menstrual Cycle; Middle Aged; Mifepristone; Uterine Neoplasms	2022
Mifepristone inhibits IGF-1 signaling pathway in the treatment of uterine leiomyomas. Drug design, development and therapy, 2019, Volume: 13 Topics: Adult; Antineoplastic Agents; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Female; Humans; Insulin-Like Growth Factor I; Leiomyoma; Mifepristone; Signal Transduction; Tumor Cells, Cultured; Uterine Neoplasms	2019
Targeting DNA Methylation Depletes Uterine Leiomyoma Stem Cell-enriched Population by Stimulating Their Differentiation. Endocrinology, 2020, 10-01, Volume: 161, Issue:10 Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Count; Cell Differentiation; Cells, Cultured; DNA Methylation; Female; Humans; Leiomyoma; Mice; Mice, SCID; Mice, Transgenic; Middle Aged; Mifepristone; Molecular Targeted Therapy; Neoplastic Stem Cells; Uterine Neoplasms; Xenograft Model Antitumor Assays	2020
Comparison between radiofrequency ablation combined with mifepristone and radiofrequency ablation for large uterine fibroids. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2021, Volume: 38, Issue:1 Topics: Female; Humans; Leiomyoma; Mifepristone; Quality of Life; Radiofrequency Ablation; Retrospective Studies; Treatment Outcome; Uterine Neoplasms	2021
The use of mifepristone in abortion associated with an increased risk of uterine leiomyomas. Medicine, 2017, Volume: 96, Issue:17 Topics: Abortion, Induced; Adult; Case-Control Studies; Dose-Response Relationship, Drug; Educational Status; Female; Humans; Leiomyoma; Logistic Models; Menstruation; Middle Aged; Mifepristone; Multivariate Analysis; Odds Ratio; Parity; Retrospective Studies; Risk Factors; Surveys and Questionnaires; Uterine Neoplasms; Vaginitis; Young Adult	2017
Progesterone receptor antagonist provides palliative effects for uterine leiomyoma through a Bcl-2/Beclin1-dependent mechanism. Bioscience reports, 2019, 07-31, Volume: 39, Issue:7 Topics: Adult; Apoptosis; Autophagic Cell Death; Beclin-1; Female; Humans; Leiomyoma; Middle Aged; Mifepristone; Palliative Care; Proto-Oncogene Proteins c-bcl-2; Receptors, Progesterone; Uterine Neoplasms	2019
Mifepristone inhibits extracellular matrix formation in uterine leiomyoma. Fertility and sterility, 2016, Volume: 105, Issue:4 Topics: Cell Line, Transformed; Dose-Response Relationship, Drug; Extracellular Matrix; Female; Hormone Antagonists; Humans; Leiomyoma; Mifepristone; Promegestone; Tumor Cells, Cultured; Uterine Neoplasms	2016
Medical abortion in women with large uterine fibroids: a case series. Contraception, 2016, Volume: 94, Issue:5 Topics: Abortifacient Agents; Abortion, Induced; Administration, Intravaginal; Adult; Drug Administration Schedule; Female; Gestational Age; Humans; Leiomyoma; Maryland; Mifepristone; Misoprostol; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Pregnancy Trimester, Second; Uterine Neoplasms	2016
Ovarian steroid hormones modulate the expression of progesterone receptors and histone acetylation patterns in uterine leiomyoma cells. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2017, Volume: 33, Issue:8 Topics: Adult; Cells, Cultured; Estradiol; Estrogens; Female; Gene Expression Regulation, Neoplastic; Histone Acetyltransferases; Histone Deacetylases; Hormone Antagonists; Humans; Leiomyoma; Middle Aged; Mifepristone; Myometrium; Neoplasm Proteins; Progesterone; Progestins; Receptors, Progesterone; Tumor Cells, Cultured; Uterine Neoplasms	2017
CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstetrics and gynecology, 2008, Volume: 112, Issue:3 Topics: Female; Hormone Antagonists; Humans; Leiomyoma; Mifepristone; Norpregnadienes; Quality of Life; Randomized Controlled Trials as Topic; Uterine Neoplasms	2008
Progestins activate the AKT pathway in leiomyoma cells and promote survival. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:5 Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Female; Fluorescent Antibody Technique; Forkhead Box Protein O1; Forkhead Transcription Factors; Humans; Leiomyoma; Mifepristone; Oncogene Protein v-akt; Phosphorylation; Progestins; Promegestone; Signal Transduction; Uterine Neoplasms	2009
Mifepristone for the treatment of uterine leiomyomas: methodological issues and clinical implications. Obstetrics and gynecology, 2009, Volume: 113, Issue:3 Topics: Female; Hormone Antagonists; Humans; Leiomyoma; Mifepristone; Organ Size; Uterine Neoplasms; Uterus	2009
Re: Low-dose mifepristone: Effects on the endometrium. Aust N Z J Obstet Gynaecol 2009; 49: 77-83. The Australian & New Zealand journal of obstetrics & gynaecology, 2009, Volume: 49, Issue:3 Topics: Endometrium; Female; Hormone Antagonists; Humans; Leiomyoma; Menorrhagia; Mifepristone; Uterine Neoplasms	2009
Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:11 Topics: Adult; Amino Acid Transport System y+; Cell Survival; DNA Primers; Female; Follicular Phase; Fusion Regulatory Protein 1, Heavy Chain; Fusion Regulatory Protein 1, Light Chains; Gene Expression Regulation, Neoplastic; Humans; Leiomyoma; Luteal Phase; Menstruation; Middle Aged; Mifepristone; Polymerase Chain Reaction; Progesterone; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Uterine Neoplasms	2009
Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. Cancer research, 2010, Feb-15, Volume: 70, Issue:4 Topics: Apoptosis Regulatory Proteins; Cell Cycle Proteins; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Hormone Antagonists; Humans; Leiomyoma; Mifepristone; Progesterone; Promoter Regions, Genetic; Receptors, Progesterone; Repressor Proteins; Signal Transduction; Trans-Activators; Transcription Factors; Tumor Burden; Tumor Cells, Cultured; Uterine Neoplasms	2010
Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2010, Volume: 109, Issue:2 Topics: Adult; Anemia; Female; Hormone Antagonists; Humans; Leiomyoma; Middle Aged; Mifepristone; Organ Size; Pain; Quality of Life; Randomized Controlled Trials as Topic; Ultrasonography; Uterine Neoplasms; Uterus	2010
Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology, 2010, Volume: 151, Issue:6 Topics: Animals; Estradiol; Estrogen Receptor alpha; Female; Humans; Immunohistochemistry; In Situ Nick-End Labeling; In Vitro Techniques; Leiomyoma; Mice; Mifepristone; Myometrium; Progesterone; Receptors, Progesterone; Transplantation, Heterologous; Uterine Neoplasms	2010
LAT1 regulates growth of uterine leiomyoma smooth muscle cells. Reproductive sciences (Thousand Oaks, Calif.), 2010, Volume: 17, Issue:9 Topics: Adult; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Female; Hormone Antagonists; Humans; Large Neutral Amino Acid-Transporter 1; Leiomyoma; Middle Aged; Mifepristone; Myocytes, Smooth Muscle; Myometrium; Progesterone; RNA Interference; RNA, Messenger; Uterine Neoplasms	2010
Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone. Human pathology, 2011, Volume: 42, Issue:7 Topics: Adult; Endometrium; Female; Hormone Antagonists; Humans; Leiomyoma; Middle Aged; Mifepristone; Receptors, Progesterone; Uterine Neoplasms	2011
Genome-wide progesterone receptor binding: cell type-specific and shared mechanisms in T47D breast cancer cells and primary leiomyoma cells. PloS one, 2012, Volume: 7, Issue:1 Topics: Adult; Base Sequence; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Hormone Antagonists; Humans; Leiomyoma; Membrane Proteins; Middle Aged; Mifepristone; Nucleotide Motifs; Oligonucleotide Array Sequence Analysis; Perilipin-2; Position-Specific Scoring Matrices; Receptors, Progesterone; Response Elements; Tumor Cells, Cultured; Uterine Neoplasms	2012
Pharmacokinetic evaluation of ulipristal acetate for uterine leiomyoma treatment. Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:7 Topics: Adult; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Female; Hormone Antagonists; Humans; Leiomyoma; Menorrhagia; Mifepristone; Norpregnadienes; Progesterone; Receptors, Progesterone; Uterine Neoplasms	2012
RU486 inhibits expression of lysophosphatidic acid induced glycodelin. American journal of obstetrics and gynecology, 2005, Volume: 192, Issue:4 Topics: Adult; Base Sequence; Biopsy, Needle; Case-Control Studies; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Immunohistochemistry; Leiomyoma; Lysophospholipids; Middle Aged; Mifepristone; Molecular Sequence Data; Probability; Reference Values; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Tumor Cells, Cultured; Uterine Neoplasms	2005
[Effects of estrogen, progestin and mifepristone on endometrial carcinoma cell lines]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2005, Jun-18, Volume: 37, Issue:3 Topics: Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Estradiol; Female; Humans; Mifepristone; Progesterone; Uterine Neoplasms	2005
Progesterone regulates HLA-G gene expression through a novel progesterone response element. Human reproduction (Oxford, England), 2006, Volume: 21, Issue:10 Topics: Breast Neoplasms; Cell Line; Cell Line, Tumor; Choriocarcinoma; DNA Primers; Female; Gene Expression Regulation; Genes, Reporter; Histocompatibility Antigens Class I; HLA Antigens; HLA-G Antigens; Humans; Mifepristone; Pregnancy; Progesterone; Promoter Regions, Genetic; Receptors, Progesterone; Uterine Neoplasms	2006
Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma. Obstetrics and gynecology, 2007, Volume: 109, Issue:2 Pt2 Topics: Diagnosis, Differential; Female; Hormone Antagonists; Humans; Leiomyosarcoma; Middle Aged; Mifepristone; Neoplasm Recurrence, Local; Neoplasm Staging; Radiography; Receptors, Progesterone; Uterine Neoplasms	2007
Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. Molecular pharmacology, 2008, Volume: 73, Issue:3 Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Choriocarcinoma; Dose-Response Relationship, Drug; Female; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Luciferases; Mifepristone; Mutation; Neoplasm Proteins; Placenta; Pregnancy; Progesterone; Promoter Regions, Genetic; Protein Isoforms; Receptors, Progesterone; Response Elements; Statistics as Topic; Transcription, Genetic; Transfection; Uterine Neoplasms	2008
Termination of a molar pregnancy using mifepristone and gemeprost. British journal of obstetrics and gynaecology, 1994, Volume: 101, Issue:7 Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Alprostadil; Female; Humans; Hydatidiform Mole; Mifepristone; Pregnancy; Uterine Neoplasms	1994
The regulation of fibroid growth: time for a re-think? British journal of obstetrics and gynaecology, 1993, Volume: 100, Issue:11 Topics: Estradiol; Female; Gonadotropin-Releasing Hormone; Humans; Leiomyoma; Mifepristone; Pregnancy; Progesterone; Uterine Neoplasms	1993
[The use of sulprostone (Nalador) in the evacuation of uterine contents. Apropos of 32 cases at the Department of Gynecology, University Hospital Center, Nîmes, over 2 years (a retrospective study)]. Journal de gynecologie, obstetrique et biologie de la reproduction, 1993, Volume: 22, Issue:4 Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adolescent; Adult; Cicatrix; Contraindications; Dinoprostone; Drug Tolerance; Female; France; Gestational Age; Humans; Hydatidiform Mole; Infusions, Intravenous; Injections, Intramuscular; Injections, Intravenous; Mifepristone; Misoprostol; Polyhydramnios; Pregnancy; Retrospective Studies; Time Factors; Uterine Diseases; Uterine Neoplasms	1993
Regression of uterine leiomyomata in response to the antiprogesterone RU 486. The Journal of clinical endocrinology and metabolism, 1993, Volume: 76, Issue:2 Topics: Adolescent; Adult; Androstenedione; Bone Density; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Follicle Stimulating Hormone; Humans; Hysterectomy; Immunohistochemistry; Leiomyoma; Luteinizing Hormone; Middle Aged; Mifepristone; Myometrium; Progesterone; Receptors, Estradiol; Receptors, Progesterone; Testosterone; Uterine Neoplasms	1993
Progestin-dependent stimulation of the human leukemia inhibitory factor promoter in SKUT-1B uterine tumor cells. Journal of reproductive immunology, 1997, Volume: 33, Issue:3 Topics: Female; Gene Expression Regulation, Neoplastic; Growth Inhibitors; Humans; Interleukin-6; Jurkat Cells; Leukemia Inhibitory Factor; Lymphokines; Medroxyprogesterone Acetate; Mifepristone; Progestins; Promoter Regions, Genetic; Receptors, Progesterone; RNA, Messenger; Sequence Deletion; Transfection; Tumor Cells, Cultured; Uterine Neoplasms	1997
Tamoxifen-mediated anti-cellular effect against a choriocarcinoma cell line. International journal of oncology, 1998, Volume: 12, Issue:5 Topics: Cell Line; Cell Survival; Choriocarcinoma; Estrogen Antagonists; Female; Hormone Antagonists; Humans; Kinetics; Mifepristone; Pregnancy; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trophoblasts; Uterine Neoplasms	1998
[Effect of mifepristone on the expression of progesterone receptor messenger RNA and protein in uterine leiomyomata]. Zhonghua fu chan ke za zhi, 1998, Volume: 33, Issue:4 Topics: Adult; Female; Gene Expression; Humans; Leiomyoma; Middle Aged; Mifepristone; Receptors, Progesterone; RNA, Messenger; Uterine Neoplasms	1998
Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. Gynecologic oncology, 2000, Volume: 78, Issue:3 Pt 1 Topics: Abortifacient Agents, Steroidal; Dilatation and Curettage; Female; Humans; Hydatidiform Mole; Mifepristone; Oxytocin; Pregnancy; Prostaglandins; Retrospective Studies; Uterine Neoplasms; Vacuum Curettage	2000
Effects of mifepristone (RU486) treatment on the development of uterine adenomyosis induced by pituitary grafting in mice. Life sciences, 2000, Oct-20, Volume: 67, Issue:22 Topics: Adenomyoma; Animals; Anticarcinogenic Agents; Endometrium; Female; Mice; Mice, Inbred Strains; Mifepristone; Organ Size; Pituitary Gland; Receptors, Progesterone; Stromal Cells; Uterine Neoplasms; Uterus; von Willebrand Factor	2000
[Clinical application of mifepristone in obstetrics and gynecology]. Zhonghua fu chan ke za zhi, 1999, Volume: 34, Issue:5 Topics: Abortifacient Agents, Steroidal; Contraceptives, Postcoital, Synthetic; Endometriosis; Female; Humans; Leiomyoma; Mifepristone; Pregnancy; Uterine Neoplasms	1999
[National symposium on clinical application of mifepristone in obstetrics and gynecology]. Zhonghua fu chan ke za zhi, 1999, Volume: 34, Issue:5 Topics: Abortifacient Agents, Steroidal; Contraceptives, Postcoital, Synthetic; Female; Humans; Mifepristone; Pregnancy; Pregnancy, Ectopic; Uterine Neoplasms	1999
[Effects of mifepristone on choriocarcinoma cell line JAR in vitro]. Zhonghua fu chan ke za zhi, 1999, Volume: 34, Issue:9 Topics: Cell Division; Choriocarcinoma; Chorionic Gonadotropin; Female; Humans; Ki-67 Antigen; Mifepristone; Pregnancy; Tumor Cells, Cultured; Uterine Neoplasms	1999
[Effects of mifepristone on estrogen and progestin receptors in human uterine leiomyoma]. Zhonghua fu chan ke za zhi, 2000, Volume: 35, Issue:2 Topics: Adult; Female; Hormone Antagonists; Humans; Leiomyoma; Middle Aged; Mifepristone; Receptors, Estrogen; Receptors, Progesterone; Uterine Neoplasms	2000
Effect of mifepristone on estrogen and progesterone receptors in human endometrial and endometriotic cells in vitro. Fertility and sterility, 2002, Volume: 77, Issue:5 Topics: Adult; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Endometriosis; Endometrium; Female; Follicular Phase; Hormone Antagonists; Humans; Immunohistochemistry; Leiomyoma; Luteal Phase; Mifepristone; Osmolar Concentration; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Uterine Neoplasms	2002
The biological effects of macrophage-colony-stimulating factor induced by progestin on growth and differentiation of endometrial adenocarcinoma cells. International journal of cancer, 1991, Sep-09, Volume: 49, Issue:2 Topics: Adenocarcinoma; Cell Differentiation; Female; Genes, fms; Humans; Macrophage Colony-Stimulating Factor; Mifepristone; Progestins; Receptor, Macrophage Colony-Stimulating Factor; RNA, Messenger; Tumor Cells, Cultured; Uterine Neoplasms	1991
Progesterone dependence and extratrophoblastic origin of pregnancy-associated plasma protein-A (PAPP-A) in early pregnancy. Archives of gynecology, 1986, Volume: 237, Issue:3 Topics: Abortifacient Agents, Steroidal; Abortion, Habitual; Abortion, Induced; Adolescent; Adult; Chorionic Gonadotropin; Culture Techniques; Decidua; Estrenes; Female; Humans; Hydatidiform Mole; Middle Aged; Mifepristone; Pregnancy; Pregnancy Proteins; Pregnancy Trimester, First; Pregnancy-Associated Plasma Protein-A; Progesterone; Prolactin; Trophoblasts; Uterine Neoplasms	1986
RU486, a progestin antagonist, binds to progesterone receptors in a human endometrial cancer cell line and reverses the growth inhibition by progestins. Journal of steroid biochemistry, 1988, Volume: 31, Issue:2 Topics: Binding, Competitive; Cell Division; Cellulose; Cytoplasm; DNA; Estrenes; Female; Glycogen; Humans; Mifepristone; Periodic Acid-Schiff Reaction; Progestins; Promegestone; Receptors, Progesterone; Staining and Labeling; Tumor Cells, Cultured; Uterine Neoplasms	1988
Mechanism of antitumoral activity of medroxyprogesterone acetate for endometrial cancer. Nihon Sanka Fujinka Gakkai zasshi, 1989, Volume: 41, Issue:11 Topics: Antineoplastic Agents; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Mifepristone; Norethindrone; Receptors, Progesterone; Tumor Cells, Cultured; Tumor Stem Cell Assay; Uterine Neoplasms	1989
[Progestogen therapy in the treatment of endometrial cancer--clinical results and mechanism of steroid action]. Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:4 Pt 2-1 Topics: Estrenes; Female; Humans; In Vitro Techniques; Medroxyprogesterone; Medroxyprogesterone Acetate; Mifepristone; Neoplasms, Hormone-Dependent; Norethindrone; Norgestrel; Progesterone Congeners; Receptors, Progesterone; Tumor Stem Cell Assay; Uterine Neoplasms	1988